CCR2-Dependent Recruitment of Tregs and Monocytes Following Radiotherapy Is Associated with TNFα-Mediated Resistance.

abstract：:Immunotherapies targeting T lymphocytes are revolutionizing cancer therapy but only benefit a subset of patients, especially in colorectal cancer. Thus, additional insight into the tumor microenvironment (TME) is required. Eosinophils are bone marrow-derived cells that have been largely studied in the context of aller...

journal_title：Cancer immunology research

authors： Reichman H,Itan M,Rozenberg P,Yarmolovski T,Brazowski E,Varol C,Gluck N,Shapira S,Arber N,Qimron U,Karo-Atar D,Lee JJ,Munitz A

更新日期：2019-03-01 00:00:00

abstract：:Infectious agents play an etiologic role in approximately 20% of cancer cases worldwide. Eleven pathogens (seven viruses, three parasites, and one bacterium) are known to contribute to oncogenesis either directly via the expression of their protein products or indirectly via chronic inflammation. Although prevention o...

journal_title：Cancer immunology research

authors： Vandeven N,Nghiem P

更新日期：2014-01-01 00:00:00

abstract：:Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable successes in fighting B-cell leukemias/lymphomas. Promising response rates are reported in patients treated with B-cell maturation antigen (BCMA) CAR T cells for multiple myeloma. However, responses appear to be nondurable, highlighting the need to ex...

journal_title：Cancer immunology research

authors： Globerson Levin A,Rawet Slobodkin M,Waks T,Horn G,Ninio-Many L,Deshet Unger N,Ohayon Y,Suliman S,Cohen Y,Tartakovsky B,Naparstek E,Avivi I,Eshhar Z

更新日期：2020-12-01 00:00:00

abstract：:Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States. Less than 6% of patients survive beyond the fifth year due to inadequate early diagnostics and ineffective treatment options. Our laboratory has developed an allogeneic, granulocyte-macrophage colony-stimulating factor (GM-CSF...

journal_title：Cancer immunology research

authors： Jhaveri DT,Kim MS,Thompson ED,Huang L,Sharma R,Klein AP,Zheng L,Le DT,Laheru DA,Pandey A,Jaffee EM,Anders RA

更新日期：2016-03-01 00:00:00

abstract：:In the past five decades, the role for lymphocytes in host immune response to tumors has been shown, at least in some patients, to be a critical component in disease prognosis. Also, the heterogeneity of lymphocytes has been documented, including the existence of regulatory T cells that suppress the immune response. A...

journal_title：Cancer immunology research

authors： Mihm MC Jr,Mulé JJ

更新日期：2015-08-01 00:00:00

abstract：:Despite HER2-targeted therapies improving the outcome of HER2+ breast cancer, many patients experience resistance and metastatic progression. Cancer stem cells (CSC) play a role in this resistance and progression, thus combining HER2 targeting with CSC inhibition could improve the management of HER2+ breast cancer. Th...

journal_title：Cancer immunology research

authors： Conti L,Bolli E,Di Lorenzo A,Franceschi V,Macchi F,Riccardo F,Ruiu R,Russo L,Quaglino E,Donofrio G,Cavallo F

更新日期：2020-08-01 00:00:00

abstract：:The transcription factor T-bet controls the Th1 genetic program in T cells for effective antitumor responses. Anti-CTLA-4 immunotherapy elicits dramatic antitumor responses in mice and in human patients; however, factors that regulate T-bet expression during an antitumor response mediated by anti-CTLA-4 remain to be e...

journal_title：Cancer immunology research

authors： Chen H,Fu T,Suh WK,Tsavachidou D,Wen S,Gao J,Ng Tang D,He Q,Sun J,Sharma P

更新日期：2014-02-01 00:00:00

abstract：:Accumulating preclinical and clinical evidence indicates that the success of several anticancer agents-including some conventional chemotherapeutics, targeted anticancer agents as well as specific forms of radiotherapy-depends (at least in part) on their ability to stimulate anticancer immune responses. Such immunosti...

journal_title：Cancer immunology research

authors： Galluzzi L,Zitvogel L,Kroemer G

更新日期：2016-11-01 00:00:00

abstract：:Recruitment of myeloid-derived suppressor cells (MDSC) into the tumor microenvironment (TME) contributes to cancer immune evasion. MDSCs express the chemokine receptor CXCR2, and inhibiting CXCR2 suppresses the recruitment of MDSCs into the tumor and the premetastatic niche. Here, we compared the growth and metastasis...

journal_title：Cancer immunology research

authors： Yang J,Yan C,Vilgelm AE,Chen SC,Ayers GD,Johnson CA,Richmond A

更新日期：2020-11-11 00:00:00

abstract：:The prognosis is very dismal for patients with relapsed CD20(+) B-cell non-Hodgkin lymphoma (B-NHL). Facilitating the development of alternative novel therapeutic strategies is required to improve outcomes in patients with recurrent/refractory CD20(+) B-NHL. In this study, we investigated functional activities of anti...

journal_title：Cancer immunology research

authors： Chu Y,Hochberg J,Yahr A,Ayello J,van de Ven C,Barth M,Czuczman M,Cairo MS

更新日期：2015-04-01 00:00:00

abstract：:Tumor-infiltrating lymphocytes (TIL) in colorectal cancer liver metastases (CLM) have been associated with more favorable patient outcomes, but whether MHC class I (MHC-I) expression on cancer cells affects prognosis is uncertain. Immunohistochemistry was performed on a tissue microarray of 158 patients with CLM, who ...

journal_title：Cancer immunology research

authors： Turcotte S,Katz SC,Shia J,Jarnagin WR,Kingham TP,Allen PJ,Fong Y,D'Angelica MI,DeMatteo RP

更新日期：2014-06-01 00:00:00

abstract：:Hypoxia-driven, A2A adenosine receptor (A2AR)-mediated (hypoxia-A2-adenosinergic), T-cell-autonomous immunosuppression was first recognized as critical and nonredundant in protecting normal tissues from inflammatory damage and autoimmunity. However, this immunosuppressive mechanism can be highjacked by bacteria and tu...

journal_title：Cancer immunology research

authors： Sitkovsky MV,Hatfield S,Abbott R,Belikoff B,Lukashev D,Ohta A

更新日期：2014-07-01 00:00:00

abstract：:Solid tumors are refractory to cellular immunotherapies in part because they contain suppressive immune effectors such as myeloid-derived suppressor cells (MDSCs) that inhibit cytotoxic lymphocytes. Strategies to reverse the suppressive tumor microenvironment (TME) should also attract and activate immune effectors wit...

journal_title：Cancer immunology research

authors： Parihar R,Rivas C,Huynh M,Omer B,Lapteva N,Metelitsa LS,Gottschalk SM,Rooney CM

更新日期：2019-03-01 00:00:00

abstract：:SLAMF6, a member of the SLAM (signaling lymphocyte activation molecules) family, is a homotypic-binding immune receptor expressed on NK, T, and B lymphocytes. Phosphorylation variance between T-cell subclones prompted us to explore its role in anti melanoma immunity. Using a 203-amino acid sequence of the human SLAMF6...

journal_title：Cancer immunology research

authors： Eisenberg G,Engelstein R,Geiger-Maor A,Hajaj E,Merims S,Frankenburg S,Uzana R,Rutenberg A,Machlenkin A,Frei G,Peretz T,Lotem M

更新日期：2018-02-01 00:00:00

abstract：:Type I interferon (IFN-I) is a class of antiviral immunomodulatory cytokines involved in many stages of tumor initiation and progression. IFN-I acts directly on tumor cells to inhibit cell growth and indirectly by activating immune cells to mount antitumor responses. To understand the role of endogenous IFN-I in spont...

journal_title：Cancer immunology research

authors： Castiello L,Sestili P,Schiavoni G,Dattilo R,Monque DM,Ciaffoni F,Iezzi M,Lamolinara A,Sistigu A,Moschella F,Pacca AM,Macchia D,Ferrantini M,Zeuner A,Biffoni M,Proietti E,Belardelli F,Aricò E

更新日期：2018-06-01 00:00:00

abstract：:Despite the rapid progress in the development of novel adoptive T-cell therapies, the clinical benefits in treatment of established tumors have remained modest. Several immune evasion mechanisms hinder T-cell entry into tumors and their activity within the tumor. Of note, oncolytic adenoviruses are intrinsically immun...

journal_title：Cancer immunology research

authors： Tähtinen S,Grönberg-Vähä-Koskela S,Lumen D,Merisalo-Soikkeli M,Siurala M,Airaksinen AJ,Vähä-Koskela M,Hemminki A

更新日期：2015-08-01 00:00:00

abstract：:Proneural-to-mesenchymal transition (PMT) is a common process in glioblastoma (GBM) progression that leads to increased radiotherapy resistance. However, the mechanism underlying PMT is poorly understood. Here, we found that tumor-associated macrophages triggered PMT in glioma stem cells (GSC) via small extracellular ...

journal_title：Cancer immunology research

authors： Zhang Z,Xu J,Chen Z,Wang H,Xue H,Yang C,Guo Q,Qi Y,Guo X,Qian M,Wang S,Qiu W,Gao X,Zhao R,Guo X,Li G

更新日期：2020-07-01 00:00:00

abstract：:Modulating the function of immune receptors with antibodies is ushering in a new era in cancer immunotherapy. With the notable exception of PD-1 blockade used as monotherapy, immune modulation can be associated with significant toxicities that are expected to escalate with the development of increasingly potent immune...

journal_title：Cancer immunology research

authors： Gilboa E,Berezhnoy A,Schrand B

更新日期：2015-11-01 00:00:00

abstract：:On September 25-28, 2016, in New York City, the Second International Cancer Immunotherapy Conference was cohosted by the Cancer Research Institute, the American Association for Cancer Research, the Association for Cancer Immunotherapy, and the European Academy of Tumor Immunology. This exciting conference brought toge...

journal_title：Cancer immunology research

authors： Brodsky AN,Hubbard-Lucey VM

更新日期：2016-12-01 00:00:00

abstract：:Vaccinia virus (VACV) is a double-stranded DNA virus that devotes a large portion of its 200 kbp genome to suppressing and manipulating the immune response of its host. Here, we investigated how targeted removal of immunomodulatory genes from the VACV genome impacted immune cells in the tumor microenvironment with the...

journal_title：Cancer immunology research

authors： Umer BA,Noyce RS,Franczak BC,Shenouda MM,Kelly RG,Favis NA,Desaulniers M,Baldwin TA,Hitt MM,Evans DH

更新日期：2020-05-01 00:00:00

abstract：:Programmed death 1 (PD-1) and PD ligand 1 (PD-L1) inhibitors have shown activity in metastatic clear cell renal cell carcinoma (ccRCC). Data on the activity of these agents in patients with non-clear cell RCC (nccRCC) or patients with sarcomatoid/rhabdoid differentiation are limited. In this multicenter analysis, we e...

journal_title：Cancer immunology research

authors： McKay RR,Bossé D,Xie W,Wankowicz SAM,Flaifel A,Brandao R,Lalani AA,Martini DJ,Wei XX,Braun DA,Van Allen E,Castellano D,De Velasco G,Wells JC,Heng DY,Fay AP,Schutz FA,Hsu J,Pal SK,Lee JL,Hsieh JJ,Harshman LC,Si

更新日期：2018-07-01 00:00:00

abstract：:Innate lymphoid cells (ILC) are responsible for mucosal tissue homeostasis and are involved in the progression and suppression of several types of cancer. However, the effects of ILCs on colorectal cancer are poorly understood. We characterized human ILCs in normal colon and colorectal cancer tissue, investigating the...

journal_title：Cancer immunology research

authors： Ikeda A,Ogino T,Kayama H,Okuzaki D,Nishimura J,Fujino S,Miyoshi N,Takahashi H,Uemura M,Matsuda C,Yamamoto H,Takeda K,Mizushima T,Mori M,Doki Y

更新日期：2020-06-01 00:00:00

abstract：:The goal of this study was to characterize the molecular mechanisms underlying cetuximab-mediated upregulation of HLA class I antigen-processing machinery components in head and neck cancer (HNC) cells and to determine the clinical significance of these changes in cetuximab-treated HNC patients. Flow cytometry, signal...

journal_title：Cancer immunology research

authors： Srivastava RM,Trivedi S,Concha-Benavente F,Hyun-Bae J,Wang L,Seethala RR,Branstetter BF 4th,Ferrone S,Ferris RL

更新日期：2015-08-01 00:00:00

abstract：:CD47-specific antibodies and fusion proteins that block CD47-SIRPα signaling are employed as antitumor agents for several cancers. Here, we investigated the synergistic antitumor effect of simultaneously targeting CD47 and autophagy in non-small cell lung cancer (NSCLC). SIRPαD1-Fc, a novel CD47-targeting fusion prote...

journal_title：Cancer immunology research

authors： Zhang X,Fan J,Wang S,Li Y,Wang Y,Li S,Luan J,Wang Z,Song P,Chen Q,Tian W,Ju D

更新日期：2017-05-01 00:00:00

abstract：:A posteriori evidence suggests that radiotherapy to a targeted tumor can elicit an immune-mediated abscopal (ab-scopus, away from the target) effect in non-targeted tumors, when combined with an anti-cytotoxic T-lymphocyte antigen-4 monoclonal (CTLA-4) antibody. Concurrent radiotherapy and ipilimumab (a human monoclon...

journal_title：Cancer immunology research

authors： Golden EB,Demaria S,Schiff PB,Chachoua A,Formenti SC

更新日期：2013-12-01 00:00:00

abstract：:Vaccination of patients with ovarian cancer with overlapping long peptides (OLP) from cancer-testis antigen NY-ESO-1 and poly-ICLC in Montanide-ISA-51 (Montanide) was found to consistently induce integrated immune responses (antibody, CD4(+), and CD8(+) T cells). Using detailed methods, we investigated the respective ...

journal_title：Cancer immunology research

authors： Tsuji T,Sabbatini P,Jungbluth AA,Ritter E,Pan L,Ritter G,Ferran L,Spriggs D,Salazar AM,Gnjatic S

更新日期：2013-11-01 00:00:00

abstract：:The current standard of care for treatment of metastatic renal cell carcinoma (mRCC) patients is PD-1/PD-L1 inhibitors until progression or toxicity. Here, we characterize the clinical outcomes for 19 mRCC patients who experienced an initial clinical response (any degree of tumor shrinkage), but after immune-related a...

journal_title：Cancer immunology research

authors： Martini DJ,Hamieh L,McKay RR,Harshman LC,Brandao R,Norton CK,Steinharter JA,Krajewski KM,Gao X,Schutz FA,McGregor B,Bossé D,Lalani AA,De Velasco G,Michaelson MD,McDermott DF,Choueiri TK

更新日期：2018-04-01 00:00:00

abstract：:Targeted monoclonal antibody therapy is a promising therapeutic strategy for cancer, and antibody-dependent cell-mediated cytotoxicity (ADCC) represents a crucial mechanism underlying these approaches. The majority of patients have limited responses to monoclonal antibody therapy due to the development of resistance. ...

journal_title：Cancer immunology research

authors： Aldeghaither DS,Zahavi DJ,Murray JC,Fertig EJ,Graham GT,Zhang YW,O'Connell A,Ma J,Jablonski SA,Weiner LM

更新日期：2019-02-01 00:00:00

abstract：:Immune checkpoint inhibitors are promising treatments for patients with a variety of malignancies. Toward understanding the determinants of response to immune checkpoint inhibitors, it was previously demonstrated that the presence of somatic mutations is associated with benefit from checkpoint inhibition. A hypothesis...

journal_title：Cancer immunology research

authors： Nathanson T,Ahuja A,Rubinsteyn A,Aksoy BA,Hellmann MD,Miao D,Van Allen E,Merghoub T,Wolchok JD,Snyder A,Hammerbacher J

更新日期：2017-01-01 00:00:00

abstract：:New immunotherapeutic strategies are needed to induce effective antitumor immunity in all cancer patients. Malignant mesothelioma is characterized by a poor prognosis and resistance to conventional therapies. Infiltration of tumor-associated macrophages (TAM) is prominent in mesothelioma and is linked to immune suppre...

journal_title：Cancer immunology research

authors： Dammeijer F,Lievense LA,Kaijen-Lambers ME,van Nimwegen M,Bezemer K,Hegmans JP,van Hall T,Hendriks RW,Aerts JG

更新日期：2017-07-01 00:00:00